Expression regulation of LY6E

11 May 2020

Regulation of LY6E

Recently, Pfaender et al. (2020) reported that the lymphocyte antigen 6 complex, locus E (LY6E) protein potently restricts cellular infection by multiple coronaviruses, including SARS-CoV-2. Using GENEVESTIGATOR® across multiple compendia and platforms, we screened thousands of experimental conditions to study the gene expression regulation of LY6E. Here are some of the most significant effects we found:

Condition Description Fold-change
IFNb-1a (Avonex) HS-01577 / Neutrophils isolated from peripheral blood samples of patients with multiple sclerosis 24 hours after the first treatment with IFNb-1A (Avonex). Control: patients before treatment. 137x upregulation
Influenza HS-03257 / Plasmacytoid dendritic cells isolated from the blood of healthy donors were treated 24h with influenza A/PR/8/34 (H1N1) virus. Control: Plasmacytoid dendritic cells isolated from healthy donors. 20x upregulation
Lupus LY6E is strongly upregulated in several SLE case-control studies 10-40x upregulation
IFM-a2b HS-00230 / Immature dendritic cells treated with 1000 u/ml of IFN-a2b. Control: without treatment 7x upregulation
Brefeldin A HS-01936 / LY6E is downregulated in response to Brefeldin A treatment. 6x downregulation
Sepsis HS-01577 / LY6E is strongly downregulated in neutrophils isolated from peripheral blood samples of patients with sepsis as compared to healthy subjects. 200x downregulation

Table: Conditions causing an up- or downregulation of the LY6E gene, as identified using the Perturbations tool in GENEVESTIGATOR®.